Metabolic alterations are a key hallmark of cancer cells, and the augmented synthesis and
use of nucleotide triphosphates is a critical and universal metabolic dependency of cancer …

Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

The remarkable success of immune checkpoint inhibitors demonstrates the potential of
tumour-specific CD8+ T cells to prevent and treat cancer. Although the number of lives …

Immune-checkpoint blockade has revolutionized cancer treatment, but some cancers, such
as acute myeloid leukemia (AML), do not respond or develop resistance. A potential mode of …

The recent success of cancer immunotherapies has highlighted the benefit of harnessing the
immune system for cancer treatment. Vaccines have a long history of promoting immunity to …

Despite remarkable clinical efficacy of immune checkpoint blockade (ICB) in cancer
treatment, ICB benefits for triple-negative breast cancer (TNBC) remain limited. Through …

Programmed cell death protein-1 (PD-1) is a checkpoint receptor expressed on the surface
of various immune cells. PD-L1, the natural receptor for PD-1, is mainly expressed in tumor …

The majority of advances in cancer therapy have been achieved based on developments in
public awareness, as well as novel diagnostic and therapeutic modalities. Treatment …